Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 18/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.61 |
| ▸ | F13A1 | P00488 | 2/20 | 0.50 |
| ▸ | TGM2 | P21980 | 2/20 | 0.50 |
| ▸ | TGM1 | P22735 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451965 | 0.90 | GRIN2B (0.68) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL4565563 | 0.90 | GRIN2B (0.62) | GRIN2BCYP2D6CYP2C9CYP3A4F13A1 | |
| SCHEMBL3986036 | 0.89 | GRIN2B (0.48) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL3983386 | 0.86 | GPR119 (0.56) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL3978507 | 0.85 | USP30 (0.47) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL3984875 | 0.84 | GRIN2B (0.50) | GRIN2BCYP2D6CYP2C9CYP3A4F13A1 | |
| SCHEMBL5083458 | 0.84 | GPR119 (0.60) | — | |
| SCHEMBL5354643 | 0.83 | GRIN2B (0.74) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL4464281 | 0.83 | GRIN2B (0.58) | GRIN2BCYP2D6CYP2C9CYP3A4F13A1 | |
| SCHEMBL3979867 | 0.80 | KDM4E (0.51) | F13A1TGM2TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059516-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (publ) (SE) | 2009-05-20 | — | — | EP | claimed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | claimed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | claimed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025798-A1 | PYRIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | GRIN2B 483/4885CYP2D6 835/4885CYP2C9 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.